大睿生物完成3500万美元A+轮融资

大睿生物医药科技(上海)有限公司宣布完成A+轮3500万美元融资，由LongRiver江远投资领投，资金将用于推进siRNA代谢管线项目的全球开发，并扩展中枢神经系统及其他领域的肝外递送平台。LongRiver江远投资将加入董事会。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":331045565489344,"tweetId":"331045565489344","gmtCreate":1721829601065,"gmtModify":1721829604202,"author":{"id":4100392628064900,"authorId":4100392628064900,"authorIdStr":"4100392628064900","name":"财见","avatar":"https://static.tigerbbs.com/dfecb1713c6fef32fde051255c4518f3","vip":5,"userType":5,"introduction":"美通社1954年开创了企业新闻稿发布行业的先河，于2016年成为Cision 旗下公司。","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":676,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"大睿生物完成3500万美元A+轮融资","html":"<html><head></head><body><p>大睿生物医药科技(上海)有限公司宣布完成A+轮3500万美元融资，由LongRiver江远投资领投，资金将用于推进siRNA代谢管线项目的全球开发，并扩展中枢神经系统及其他领域的肝外递送平台。LongRiver江远投资将加入董事会。</p></body></html>","htmlText":"<html><head></head><body><p>大睿生物医药科技(上海)有限公司宣布完成A+轮3500万美元融资，由LongRiver江远投资领投，资金将用于推进siRNA代谢管线项目的全球开发，并扩展中枢神经系统及其他领域的肝外递送平台。LongRiver江远投资将加入董事会。</p></body></html>","text":"大睿生物医药科技(上海)有限公司宣布完成A+轮3500万美元融资，由LongRiver江远投资领投，资金将用于推进siRNA代谢管线项目的全球开发，并扩展中枢神经系统及其他领域的肝外递送平台。LongRiver江远投资将加入董事会。","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/331045565489344","repostId":0,"isVote":1,"tweetType":1,"viewCount":20284,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":196,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/331045565489344"}